首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

导出 OA

翻译打印收藏纠错

第一作者： Douglas B,Johnson

第一单位： Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu.

作者： Douglas B,Johnson ^[1] ; Jennifer,Bordeaux ^[2] ; Ju Young,Kim ^[2] ; Christine,Vaupel ^[2] ; David L,Rimm ^[3] ; Thai H,Ho ^[4] ; Richard W,Joseph ^[4] ; Adil I,Daud ^[5] ; Robert M,Conry ^[6] ; Elizabeth M,Gaughan ^[7] ; Leonel F,Hernandez-Aya ^[8] ; Anastasios,Dimou ^[9] ; Pauline,Funchain ^[10] ; James,Smithy ^[3] ; John S,Witte ^[5] ; Svetlana B,McKee ^[6] ; Jennifer,Ko ^[10] ; John M,Wrangle ^[9] ; Bashar,Dabbas ^[2] ; Shabnam,Tangri ^[2] ; Jelveh,Lameh ^[2] ; Jeffrey,Hall ^[11] ; Joseph,Markowitz ^[12] ; Justin M,Balko ^[13] ; Naveen,Dakappagari ^[2]

作者单位： Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu. ^[1] Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California. ^[2] Yale University, New Haven, Connecticut. ^[3] Mayo Clinic, Jacksonville, Florida and Phoenix, Arizona. ^[4] University of California, San Francisco, California. ^[5] University of Alabama, Birmingham, Alabama. ^[6] University of Virginia, Charlottesville, Virginia. ^[7] Washington University in St. Louis, St. Louis, Missouri. ^[8] Medical University of South Carolina, Charleston, South Carolina. ^[9] Cleveland Clinic, Cleveland, Ohio. ^[10] Genoptix, Inc., Carlsbad, California. ^[11] Moffitt Cancer Center, Tampa, Florida. ^[12] Vanderbilt University Medical Center, Nashville, Tennessee. ^[13]